



COPY OF PAPERS  
ORIGINALLY FILED

PATENT  
454313-2280.1

4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Franciscus Antonius Maria RIJSEWIJK et al.  
Serial No. : 10/077,489  
Filed : February 15, 2002  
Title : BOVINE POLYNUCLEOTIDE VACCINE FOR  
THE INTRADERMAL ROUTE  
Group Art Unit : 1484  
Examiner : Not Yet Assigned

745 Fifth Avenue  
New York, NY 10151

I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an envelope  
addressed to: Hon. Commissioner of Patents and Trademarks  
Washington, DC 20231, on March 21, 2002.

William S. Frommer, Reg. No. 25,506

Name of Applicant, Assignee or Registered Representative

*William S. Frommer*

Signature

March 21, 2002

Date of Signature

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Supplemental to the Preliminary Amendment filed February 15, 2002, please  
amend the application as follows:

**IN THE SPECIFICATION:**

Please amend the paragraph added to page 1, before line 1, to read as follows:

20057545-032902

--This application is a divisional of application U.S. Patent Serial No. 09/232,469, filed January 15, 1999, now allowed, which in turn is a continuation-in-part of copending International Application PCT/FR97/01322 having an international filing date of 16 July 1997, and designating the U.S. and claiming priority from French application Serial No. 96/09402, filed 16 July 1996. All of the above-mentioned applications, as well as documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference. Vectors of vaccines or immunological compositions of documents cited herein or documents referenced in documents cited herein or portions of such vectors (e.g., one or more or all of regulatory sequences such as DNA for promoter, leader for secretion, terminator), may to the extent practicable with respect to the preferred host and administration route of this application, also be employed in the practice of this invention; and, DNA for vectors of vaccines or immunological compositions herein can be obtained from available sources and knowledge in the art, e.g., GeneBank, such that from this disclosure, no undue experimentation is required to make or use such vectors; see also PCT/IB97/01040, filed July 28, 1997 and designating the U.S., incorporated herein by reference. --

#### REMARKS

The amendment to the specification is made to correct the filing date of the parent application 09/232,469.

Attached hereto is a marked up version of the changes made to the specification by the present amendment. The attached page is entitled "**Version with Markings to Show Changes Made.**"


It is believed that no additional fee is due. If, however, a fee is due, please charge Deposit Account No. 50-0320.

Please issue a corrected Filing Receipt.

An early examination on the merits is respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By   
William S. Frommer  
Registration No. 25,506  
(212) 588-0800

2006230-588-0800

**APPENDIX SHOWING AMENDMENTS TO THE SPECIFICATION**

Please amend the paragraph added to page 1, before line 1, to read as follows:

--This application is a divisional of application U.S. Patent Serial No. 09/232,469, filed [July 15, 1999] January 15, 1999, now allowed, which in turn is a continuation-in-part of copending International Application PCT/FR97/01322 having an international filing date of 16 July 1997, and designating the U.S. and claiming priority from French application Serial No. 96/09402, filed 16 July 1996. All of the above-mentioned applications, as well as documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference. Vectors of vaccines or immunological compositions of documents cited herein or documents referenced in documents cited herein or portions of such vectors (e.g., one or more or all of regulatory sequences such as DNA for promoter, leader for secretion, terminator), may to the extent practicable with respect to the preferred host and administration route of this application, also be employed in the practice of this invention; and, DNA for vectors of vaccines or immunological compositions herein can be obtained from available sources and knowledge in the art, e.g., GeneBank, such that from this disclosure, no undue experimentation is required to make or use such vectors; see also PCT/IB97/01040, filed July 28, 1997 and designating the U.S., incorporated herein by reference. --